دورية أكاديمية
Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
| العنوان: | Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma |
|---|---|
| المؤلفون: | Ana Acuna-Villaorduna MD, Viswanathan Shankar Dr.P.H, Michael Wysota MD, Amanda Jirgal BA, Rafi Kabarriti MD, Sarah Bellemare MD, Inessa Goldman MD, Andreas Kaubisch MD, Santiago Aparo MD, Sanjay Goel MD, MS, Jennifer Chuy MD |
| المصدر: | Cancer Control, Vol 29 (2022) |
| بيانات النشر: | SAGE Publishing, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Introduction Perioperative therapy is standard for patients with borderline-resectable pancreatic ductal adenocarcinoma (BR-PDAC); however, an optimal neoadjuvant regimen is lacking. We assessed the efficacy of FOLFIRINOX chemotherapy followed by gemcitabine-based chemoradiation as preoperative therapy. Methods Patients received 4 cycles of FOLFIRINOX, followed by 6-weekly gemcitabine with concomitant intensity-modulated radiation. The primary endpoint was the R0 resection rate. Secondary outcomes included resection rate, overall-response, overall survival (OS), progression-free survival (PFS), and tolerability. The trial was terminated early due to slow accrual. A Simon’s optimal two-stage phase II trial single arm design was used. The primary hypothesis of treatment efficacy was tested using a multistage group sequential inference procedure. The secondary failure time analysis endpoints were assessed using the Kaplan-Meier procedure and the Cox regression model. Results A total of 22 patients enrolled in the study, 18 (81.8%) completed neoadjuvant treatment. The bias corrected R0 rate was 55.6% (90% CI: 33.3, 68.3; P value = .16) among patients that received at least 1 cycle of FOLFIRINOX and was 80% among patients that underwent surgery. The median OS was 35.1 months. The median PFS among patients that underwent surgery was 34 months. Conclusion An R0 resection rate of 55.6% is favorable. Neoadjuvant FOLFIRINOX followed by concomitant Gemcitabine with radiation was well-tolerated. NCT01897454 |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1526-2359 10732748 |
| العلاقة: | https://doaj.org/toc/1526-2359Test |
| DOI: | 10.1177/10732748221134411 |
| الوصول الحر: | https://doaj.org/article/5ec1ac5d0669454798a73d5d02b36860Test |
| رقم الانضمام: | edsdoj.5ec1ac5d0669454798a73d5d02b36860 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 15262359 10732748 |
|---|---|
| DOI: | 10.1177/10732748221134411 |